A randomized, controlled phase 2 trial of uproleselan, an e-selectin inhibitor, vs placebo to reduce GI toxicity in patients with multiple myeloma undergoing autologous hematopoietic cell transplant
Clinical Lymphoma, Myeloma & Leukemia（2023）
关键词
multiple myeloma,uproleselan,inhibitor,gi toxicity,e-selectin
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要